Literature DB >> 26343011

Ebola virus dynamics in mice treated with favipiravir.

Vincent Madelain1, Lisa Oestereich2, Frederik Graw3, Thi Huyen Tram Nguyen1, Xavier de Lamballerie4, France Mentré1, Stephan Günther2, Jeremie Guedj5.   

Abstract

The polymerase inhibitor favipiravir is a candidate for the treatment of Ebola virus disease. Here, we designed a mathematical model to characterize the viral dynamics in 20 mice experimentally infected with Ebola virus, which were either left untreated or treated with favipiravir at 6 or 8days post infection. This approach provided estimates of kinetic parameters of Ebola virus reproduction, such as the half-life of productively infected cells, of about 6h, and the basic reproductive number which indicates that virus produced by a single infected cell productively infects about 9 new cells. Furthermore, the model predicted that favipiravir efficiently blocks viral production, reaching an antiviral effectiveness of 95% and 99.6% at 2 and 6days after initiation of treatment, respectively. The model could be particularly helpful to guide future studies evaluating favipiravir in larger animals.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Ebola; Favipiravir; Modeling; Viral kinetics

Mesh:

Substances:

Year:  2015        PMID: 26343011     DOI: 10.1016/j.antiviral.2015.08.015

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  26 in total

1.  Favipiravir Pharmacokinetics in Nonhuman Primates and Insights for Future Efficacy Studies of Hemorrhagic Fever Viruses.

Authors:  Vincent Madelain; Jérémie Guedj; France Mentré; Thi Huyen Tram Nguyen; Frédéric Jacquot; Lisa Oestereich; Takumi Kadota; Koichi Yamada; Anne-Marie Taburet; Xavier de Lamballerie; Hervé Raoul
Journal:  Antimicrob Agents Chemother       Date:  2016-12-27       Impact factor: 5.191

2.  Successful treatment of Marburg virus with orally administrated T-705 (Favipiravir) in a mouse model.

Authors:  Wenjun Zhu; Zirui Zhang; Shihua He; Gary Wong; Logan Banadyga; Xiangguo Qiu
Journal:  Antiviral Res       Date:  2018-02-03       Impact factor: 5.970

Review 3.  Clinical Evaluation of Ebola Virus Disease Therapeutics.

Authors:  Guodong Liu; Gary Wong; Shuo Su; Yuhai Bi; Frank Plummer; George F Gao; Gary Kobinger; Xiangguo Qiu
Journal:  Trends Mol Med       Date:  2017-08-17       Impact factor: 11.951

Review 4.  Mathematical modeling of within-host Zika virus dynamics.

Authors:  Katharine Best; Alan S Perelson
Journal:  Immunol Rev       Date:  2018-09       Impact factor: 12.988

5.  Advances in Parameter Estimation and Learning from Data for Mathematical Models of Hepatitis C Viral Kinetics.

Authors:  Vladimir Reinharz; Alexander Churkin; Harel Dahari; Danny Barash
Journal:  Mathematics (Basel)       Date:  2022-06-19

6.  Numerical schemes for solving and optimizing multiscale models with age of hepatitis C virus dynamics.

Authors:  Vladimir Reinharz; Harel Dahari; Danny Barash
Journal:  Math Biosci       Date:  2018-03-15       Impact factor: 2.144

Review 7.  Epidemiology and Management of the 2013-16 West African Ebola Outbreak.

Authors:  M L Boisen; J N Hartnett; A Goba; M A Vandi; D S Grant; J S Schieffelin; R F Garry; L M Branco
Journal:  Annu Rev Virol       Date:  2016-08-15       Impact factor: 10.431

Review 8.  Ebola Virus Infection: Review of the Pharmacokinetic and Pharmacodynamic Properties of Drugs Considered for Testing in Human Efficacy Trials.

Authors:  Vincent Madelain; Thi Huyen Tram Nguyen; Anaelle Olivo; Xavier de Lamballerie; Jérémie Guedj; Anne-Marie Taburet; France Mentré
Journal:  Clin Pharmacokinet       Date:  2016-08       Impact factor: 6.447

9.  Prophylactic Efficacy of Quercetin 3-β-O-d-Glucoside against Ebola Virus Infection.

Authors:  Xiangguo Qiu; Andrea Kroeker; Shihua He; Robert Kozak; Jonathan Audet; Majambu Mbikay; Michel Chrétien
Journal:  Antimicrob Agents Chemother       Date:  2016-08-22       Impact factor: 5.191

10.  Efficacy of antiviral therapies for COVID-19: a systematic review of randomized controlled trials.

Authors:  Charan Thej Reddy Vegivinti; Kirk W Evanson; Hannah Lyons; Izzet Akosman; Averi Barrett; Nicole Hardy; Bernadette Kane; Praneeth Reddy Keesari; Yashwitha Sai Pulakurthi; Erin Sheffels; Prasanth Balasubramanian; Richa Chibbar; Spandana Chittajallu; Kathryn Cowie; J Karon; Lauren Siegel; Ranita Tarchand; Caleb Zinn; Nitin Gupta; Kevin M Kallmes; Kavitha Saravu; Jillienne Touchette
Journal:  BMC Infect Dis       Date:  2022-01-31       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.